BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 31609094)

  • 1. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
    Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ
    Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
    Yang RK; Zhao P; Lu C; Luo J; Hu R
    Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
    Dalin MG; Desrichard A; Katabi N; Makarov V; Walsh LA; Lee KW; Wang Q; Armenia J; West L; Dogan S; Wang L; Ramaswami D; Ho AL; Ganly I; Solit DB; Berger MF; Schultz ND; Reis-Filho JS; Chan TA; Morris LG
    Clin Cancer Res; 2016 Sep; 22(18):4623-33. PubMed ID: 27103403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
    Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
    Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
    Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
    Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
    Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
    Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of apocrine salivary duct carcinoma.
    Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
    Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
    Mitani Y; Rao PH; Maity SN; Lee YC; Ferrarotto R; Post JC; Licitra L; Lippman SM; Kies MS; Weber RS; Caulin C; Lin SH; El-Naggar AK
    Clin Cancer Res; 2014 Dec; 20(24):6570-81. PubMed ID: 25316813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
    Nardi V; Sadow PM; Juric D; Zhao D; Cosper AK; Bergethon K; Scialabba VL; Batten JM; Borger DR; Iafrate AJ; Heist RS; Lawrence DP; Flaherty KT; Bendell JC; Deschler D; Li Y; Wirth LJ; Dias-Santagata D
    Clin Cancer Res; 2013 Jan; 19(2):480-90. PubMed ID: 23186780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
    Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
    Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
    van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
    Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
    Udager AM; Chiosea SI
    Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
    Liang L; Williams MD; Bell D
    Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
    Ryu HJ; Koh YW; Yoon SO
    Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities.
    Alame M; Cornillot E; Cacheux V; Tosato G; Four M; De Oliveira L; Gofflot S; Delvenne P; Turtoi E; Cabello-Aguilar S; Nishiyama M; Turtoi A; Costes-Martineau V; Colinge J
    Theranostics; 2020; 10(10):4383-4394. PubMed ID: 32292502
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
    Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
    Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.